Results 141 to 150 of about 469,352 (221)

Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial. [PDF]

Hum Vaccin Immunother
Giriappa B, Choraria N, Ponce P, Drozd J, Su X, Lei L, Portka M, Pai S, Anderson A, Bickham K, Watson W, McElwee K.   +11 more
europepmc   +1 more source

Safety and Immunogenicity of SII's 10-Valent Pneumococcal Conjugate Vaccine (PCV10-SII) in Vietnamese Children Aged from 6 Weeks to 24 Months: An Open-Label, Single-Arm Bridging Study. [PDF]

Vaccines (Basel)
Son VT, Anh BDT, Hoan VN, Than HV, Linh BK, Giang TH, Manh NT, Thao LTT, Cuong HX, Giang DT, Dat DT, Giang LTH, Mulay SC, Sethna V, Hung PV.   +14 more
europepmc   +1 more source

Phylogenetic analysis of serotype 19A-sequence type (ST)2331 <i>Streptococcus pneumoniae</i> associated with the Pneumococcal Molecular Epidemiology Network (PMEN)34 clone predominant in Japan after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). [PDF]

Microb Genom
Koide S, Nakano S, Fujisawa T, Ito Y, Chang B, Suga S, Sugawara Y, Akeda Y, Sugai M.   +8 more
europepmc   +1 more source

Immunogenicity of DTaP-IPV-Hib and MenC vaccines in the UK when administered with a 13-valent pneumococcal conjugate vaccine

, 2008
Snape, M., Layton, H., Heath, P.T., Dymond, S., Klinger, C., Gruber, W., Baker, S., Galiza, E., Daniels, E., Pestridge, S., Faust, S.N., Tansey, S., Scott, D., John, T., Finn, A., Pollard, A.   +15 more
core   +1 more source

Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older. [PDF]

Vaccine
Altawalbeh SM, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, Smith KJ.   +7 more
europepmc   +1 more source

Assessing the Impact of Pneumococcal Conjugate Vaccines

Clinical Infectious Diseases, 2019
openaire   +2 more sources

A decade of 10-valent pneumococcal conjugate vaccine use in Lithuania: trends in invasive pneumococcal serotype dynamics. [PDF]

Front Public Health
Petrutienė A, Sinotova J, Pupienienė N, Marcinonytė R, Padvilikytė I, Razmuk J, Muralytė S, Bulavaitė A, Plečkaitytė M.   +8 more
europepmc   +1 more source

Effectiveness of the 13-valent pneumococcal conjugate vaccine against medically attended pneumococcal lower respiratory tract infection among older adults: a case-control study. [PDF]

Sci Rep
Ngamprasertchai T, Phatharodom P, Intalapaporn K, Sutthipool K, Chongtrakool P, Yungyuen T, Luvira V, Ratanasuwan W, Rattanaumpawan P, Lawpoolsri S, Pitisuttithum P.   +10 more
europepmc   +1 more source

Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review. [PDF]

Infect Dis Ther
Dunne EM, Hong L, Althouse BM, Hayford K, Jodar L, Gessner BD, Theilacker C.   +6 more
europepmc   +1 more source

Cost-effectiveness analyses of 20-valent pneumococcal conjugate vaccine in children and adults: A narrative review. [PDF]

Hum Vaccin Immunother
Shono A, Hoshi SL, Kondo M.
europepmc   +1 more source